Maynard Um
-
-
-
-
-
-
-
Cellectis (CLLS) Reiterated at Market Outperform by Citizens After MRD Clearance
-
-
-
-
-
-
-
Cellectis publishes gene editing research in Nature Communications
-
-
-
-
-
-
-
Cellectis (CLLS) Tops Q1 EPS by 7c
-
-
-
-
-
-
-
Cellectis (CLLS) PT Lowered to $10 at Oppenheimer
466,314 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


